Australia Neonatal and Prenatal Devices Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia neonatal and prenatal devices market is moving from stand-alone bedside machines towards connected, AI-assisted and wearable systems. Scanning, labour monitoring and newborn respiratory care were once separate equipment purchases, whereas hospitals now plan them together inside large new women's and babies facilities.

Three forces shape demand: steady birth volumes of nearly 300,000 a year, state and territory investment in maternity and neonatal capacity, and a shift to less invasive care that keeps babies with their mothers.

In January 2026 the Children's Hospital Westmead completed a building with a neonatal intensive care unit, in April 2026 Victoria committed AUD 249 million to western Melbourne maternity services, and in June 2026 health ministers added two conditions to newborn bloodspot screening.

Key Market Trends and Insights

• Stable demand base: The Australian Bureau of Statistics registered 292,318 births in 2024, up 1.9%, and the total fertility rate was 1.481, so device demand rests on replacement cycles and clinical upgrades rather than volume surges.
• High neonatal admission rate: The Australian Institute of Health and Welfare reports that 18% of babies born in 2023 needed special care or neonatal intensive care, including 78% of preterm babies, which sustains demand for respiratory and thermal care devices.
• State-funded capacity: Western Australia has committed AUD 1.8 billion to a new Women and Babies Hospital, and Queensland announced a Mackay Base Hospital masterplan with at least 128 new beds in August 2026.
• Wearable fetal monitoring: Oli raised AUD 6.5 million in May 2026 and won AUD 2 million from the Industry Growth Program in June 2026 to build a body-worn maternal and fetal sensor in Sydney.

Australia Neonatal and Prenatal Devices Market Size and Forecast

The market is shifting from standalone machines used on high-risk pregnancies towards connected monitoring, AI-guided scanning and gentler respiratory support for newborns. Prenatal ultrasound leads because nearly every pregnancy involves several scans, while fetal and maternal monitors advance fastest as wearable sensors and remote surveillance mature. Neonatal intensive care grows quickest among applications, and specialist clinics and imaging centres gain share among end users. New South Wales remains the largest state while Queensland grows fastest. Hospital builds, screening policy and local innovation point to durable multi-year demand rather than a cyclical uplift.

Key Takeaways: Australia Neonatal and Prenatal Devices Market

Birth Volumes and Hospital Builds Anchor Demand

Revenue is on course to rise by about 71% across the decade, from AUD 480.00 million in 2025 to AUD 819.91 million in 2035 at a 5.5% CAGR. Nearly 300,000 births a year and state-funded builds, from Westmead to Perth, turn clinical need into recurring equipment purchases.

Monitoring and Intensive Care Lead Growth

Prenatal Ultrasound Systems hold the largest revenue share, but Fetal and Maternal Monitors grow at an estimated 7.2% CAGR, Neonatal Intensive Care at 6.4% and Specialist Clinics and Imaging Centres at 6.8% through 2035. Wearable sensors and non-invasive respiratory tools drive the gains.

Oli Funds Wearable Maternal and Fetal Monitoring

Oli, an Australian medtech company, raised AUD 6.5 million in May 2026 and secured a further AUD 2 million in June 2026, moving a cordless sensor towards regulatory submission and local manufacture.

• Investors include Scale Investors, Clare Ventures and the University of Sydney
• Pivotal trials run at seven sites across Australia and the United States
• Sydney production is expected to begin later in 2026

Australia Neonatal and Prenatal Devices Market Report Summary

Key Insight

Steady births, high newborn intensive care use and large public hospital builds make this a structural market. Imaging leads, while monitoring, intensive care and Queensland grow fastest.

Key Trends in the Australia Neonatal and Prenatal Devices Market

The Australia neonatal and prenatal devices market is being shaped by regional hospital expansion, wider newborn screening, state maternity budgets and new neonatal intensive care capacity.

August 2026 - Queensland Unveils Mackay Base Hospital Expansion Masterplan

• Premier David Crisafulli and Health Minister Tim Nicholls released the masterplan on 11 August 2026, with Stage 1 adding at least 128 overnight beds.
• It expands maternity, birthing, neonatal and paediatric services and adds a new Mackay Birth Centre, with construction starting in 2027.
• Regional upgrades create equipment demand outside capital cities from 2027.

June 2026 - Health Ministers Add Two Conditions to Newborn Bloodspot Screening

• Health ministers decided in June 2026 to add mucopolysaccharidosis type 1 and type 2 to Australia's newborn bloodspot screening programs.
• They did not add Pompe disease, following Medical Services Advisory Committee advice that harms may outweigh benefits.
• States and territories now prepare implementation, extending laboratory demand tied to newborn care.

April 2026 - Victorian Budget Commits AUD 249 Million to Western Maternity Services

• The Victorian Budget 2026/27, released in April 2026, provides AUD 249 million for maternity services across Melbourne's western suburbs.
• It funds 32 post-natal beds, 1,500 more sonography appointments and extra special care nursery cots at Joan Kirner Women's and Children's Hospital.
• Added sonography capacity and nursery cots raise demand for ultrasound systems and neonatal monitoring equipment.

January 2026 - Children's Hospital Westmead Completes Stage 2 Building With Neonatal Unit

• NSW Health announced on 14 January 2026 that construction of the 14-storey Stage 2 building at Children's Hospital Westmead was complete.
• The building houses neonatal and paediatric intensive care units on two floors, within a AUD 659.1 million project.
• New intensive care rooms with medical pendants support purchases of ventilation, monitoring and thermal care devices.

Key Insight

Regional hospital builds, wider screening and state maternity budgets are broadening where and how devices are bought. New neonatal intensive care capacity shows investment moving into equipment-heavy settings.

Recent Market Developments in the Australia Neonatal and Prenatal Devices Market

Recent developments, presented from the most recent, show the Australia neonatal and prenatal devices market moving from supplier results into local start-up funding and AI-assisted scanning.

July 2026 - Drägerwerk Reports Higher Medical Sales for the First Half

• Drägerwerk published preliminary figures on 13 July 2026 showing medical division net sales of about EUR 898 million for the first half.
• That compares with EUR 851.1 million a year earlier, growth of 7.6% after currency effects.
• Draeger Australia Pty Ltd holds an active Australian Register of Therapeutic Goods listing for a Class IIb stationary infant incubator.

June 2026 - Oli Wins AUD 2 Million Industry Growth Program Funding

• Oli received AUD 2 million from the Australian Government's Industry Growth Program in June 2026, on top of an earlier AUD 1.3 million NSW Medical Devices Fund grant.
• The money establishes manufacturing of its wireless maternal and fetal wearable in Sydney, with production expected to begin later in 2026.
• Local manufacture shortens the route from Australian trials to hospital supply.

May 2026 - Fisher and Paykel Healthcare Reports Hospital Product Growth

• Fisher and Paykel Healthcare reported full-year results on 26 May 2026, with group operating revenue of NZD 2.31 billion, up 14%.
• Hospital product group revenue reached NZD 1.51 billion, up 18%, and hospital consumables rose 16%.
• Its East Tamaki campus is adding a fifth building to expand hospital product supply.

February 2026 - GE HealthCare Adds Fetoly AI to Voluson Ultrasound Systems

• GE HealthCare announced on 5 February 2026 a collaboration with Diagnoly to bring Fetoly AI into its Voluson women's health ultrasound systems.
• Fetoly gives real-time support on fetal heart and brain views and checks exam completeness, following ISUOG guidelines.
• The tool is cleared by the United States FDA and CE marked, but no TGA status was stated.

Key Insight

Recent activity combines supplier growth, local manufacturing of a wearable and AI scanning aids. The mix shows global suppliers and Australian start-ups both targeting monitoring and imaging.

Australia Neonatal and Prenatal Devices Industry Segmentation

The Expert Market Research’s report on the Australia Neonatal and Prenatal Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Prenatal Ultrasound Systems
• Fetal and Maternal Monitors
• Neonatal Incubators and Warmers
• Neonatal Respiratory Support Devices
• Neonatal Monitoring and Screening Devices
• Others

Prenatal Ultrasound Systems lead because most pregnancies involve several scans, and GE HealthCare unveiled Voluson Performance 18 and 16 in September 2025 before adding Fetoly AI in February 2026. Fetal and Maternal Monitors grow fastest at an estimated 7.2% CAGR through 2035, helped by Oli's AUD 6.5 million raise in May 2026. Neonatal Incubators and Warmers include the Dräger stationary infant incubator listed in Australia. Neonatal Respiratory Support Devices draw on Fisher and Paykel Healthcare CPAP and Ventora Medical's airway pressure monitor. Neonatal Monitoring and Screening Devices follow the July 2025 hearing framework. Others include phototherapy and resuscitation equipment.

Market Breakup by Application

• Antenatal Screening and Diagnosis
• Labour and Delivery Monitoring
• Neonatal Intensive Care
• Special Care and Postnatal Newborn Care
• Others

Antenatal Screening and Diagnosis leads because nearly 300,000 births a year each involve scanning, and Victoria funded 1,500 extra sonography appointments in April 2026. Neonatal Intensive Care grows fastest at an estimated 6.4% CAGR through 2035, as 18% of babies needed special care or intensive care in 2023 and Children's Hospital Westmead opened a new unit building in January 2026. Labour and Delivery Monitoring is where Oli's wearable is in pivotal trials. Special Care and Postnatal Newborn Care gains from Victoria's AUD 8.1 million nurse program of June 2026. Others include newborn bloodspot screening, where MPS I and II were added in June 2026.

Market Breakup by End User

• Public Hospitals
• Private Hospitals
• Specialist Clinics and Imaging Centres
• Others

Public Hospitals lead because state governments fund the large builds, including Western Australia's AUD 1.8 billion Women and Babies Hospital and the AUD 659.1 million Westmead Stage 2 project completed in January 2026. Specialist Clinics and Imaging Centres grow fastest at an estimated 6.8% CAGR through 2035, as obstetric ultrasound and AI-guided scan tools such as Fetoly move to community practices. Private Hospitals buy across ultrasound and monitoring, and Epworth HealthCare hosted the Ventora Medical usability study reported in January 2026. Others include birth centres, such as the new Mackay Birth Centre announced in August 2026, and home care.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates with 86,978 births registered in 2024 and the Westmead neonatal building completed in January 2026, and it grows at an estimated 5.3% CAGR through 2035. Queensland is fastest at an estimated 6.3%, with 58,986 births and the Mackay masterplan of August 2026. Victoria, at an estimated 5.6%, recorded 82,328 births and gained AUD 249 million in April 2026. Western Australia grows at 6.0% with a AUD 1.8 billion hospital planned, while South Australia, at 5.0%, awaits a new Women's and Children's Hospital due 2030-31. Others covers Tasmania, the ACT and the Northern Territory, growing at an estimated 5.4%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Neonatal and Prenatal Devices Market

Competition combines global imaging and critical care groups, respiratory specialists and Australian start-ups. Barriers include registration on the Australian Register of Therapeutic Goods, clinical validation, service networks and hospital tender relationships.

GE HealthCare

GE HealthCare, headquartered in Chicago, makes the Voluson women's health ultrasound range, patient monitoring and infant care equipment. Its local entity, GE Healthcare Australia Pty Ltd, is a sponsor on the Australian Register of Therapeutic Goods. In September 2025 it unveiled Voluson Performance 18 and 16 with SonoLyst automation at the ISUOG congress, and in February 2026 it announced Diagnoly Fetoly AI for fetal heart and brain scans.

Fisher and Paykel Healthcare

Fisher and Paykel Healthcare, headquartered in Auckland, New Zealand, makes infant respiratory products, including the Bubble CPAP system, Optiflow Junior 2 nasal cannula, Airvo 3 Junior and Neopuff T-Piece resuscitator. For the year to March 2026 it reported group operating revenue of NZD 2.31 billion, with hospital products up 18% to NZD 1.51 billion, and it is building a fifth building at its East Tamaki campus.

Drägerwerk

Drägerwerk, headquartered in Lübeck, Germany, makes incubators, infant warmers, ventilators and monitors for neonatal units. Draeger Australia Pty Ltd is the sponsor of an active Australian Register of Therapeutic Goods entry for a Class IIb stationary infant incubator. In July 2026 the group's preliminary figures put medical division net sales at about EUR 898 million for the first half, up from EUR 851.1 million a year earlier.

Oli

Oli is an Australian medtech company developing a cordless, body-worn sensor that tracks signals from mother and fetus and aims to assess up to 15 pregnancy and birth conditions, including fetal distress and postpartum haemorrhage. It raised AUD 6.5 million in a Series A3 round in May 2026. It is pursuing Therapeutic Goods Administration and United States FDA submissions and will manufacture in Sydney.

Other players operating in the Australia neonatal and prenatal devices market include Koninklijke Philips, Masimo, Mindray, Natus Medical, and Ventora Medical, alongside ultrasound suppliers, incubator and phototherapy makers, monitoring specialists and distributors serving public hospitals, private hospitals and imaging clinics across Australia.

Key Insight

Competition rests on registration, clinical evidence, service reach and tender relationships rather than price alone. Global groups anchor installed bases, while Australian start-ups compete in wearable monitoring.